RESEARCH ARTICLE

Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and \( \alpha_v\beta_3 \) Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells

Jiale Li¹, Ping Zhou¹*, Lan Li¹, Yan Zhang¹, Yang Shao¹, Li Tang², Shuangming Tian¹

¹ Department of Ultrasound, the Third Xiangya Hospital, Central South University, Changsha, Hunan China,
2 MDFLOW System, Corporate Park of Doral, Doral, Florida, United States of America

* zhouping1000@hotmail.com

Abstract

Objective

Hepatocellular carcinoma (HCC), mostly derived from hepatitis or cirrhosis, is one of the most common types of liver cancer. T-cell mediated immune response elicited by CD/TK double suicide gene has shown a substantial antitumor effect in HCC. Integrin \( \alpha_v\beta_3 \) over expression has been suggested to regulate the biology behavior of HCC. In this study, we investigated the strategy of incorporating CD/TK double suicide gene and anti-\( \alpha_v\beta_3 \) integrin monoclonal antibodies into cationic microbubbles (CMBS\( \alpha_v\beta_3 \)), and evaluated its killing effect in HCC cells.

Methods

To improve the transfection efficiency of targeted CD/TK double suicide gene, we adopted cationic microbubbles (CMBs), a cationic delivery agent with enhanced DNA-carrying capacity. The ultrasound and high speed shearing method was used to prepare the non-targeting cationic microbubbles (CMBs). Using the biotin-avidin bridge method, \( \alpha_v\beta_3 \) integrin antibody was conjugated to CMBs, and CMBs\( \alpha_v\beta_3 \) was generated to specifically target to HepG2 cells. The morphology and physicochemical properties of the CMBs\( \alpha_v\beta_3 \) was detected by optical microscope and zeta detector. The conjugation of plasmid and the antibody in CMBs\( \alpha_v\beta_3 \) were examined by immunofluorescent microscopy and flow cytometry. The binding capacities of CMBs\( \alpha_v\beta_3 \) and CMBs to HCC HepG2 and normal L-02 cells were compared using rosette formation assay. To detect EGFP fluorescence and examine the transfection efficiencies of CMBs\( \alpha_v\beta_3 \) and CMBs in HCC cells, fluorescence microscope and contrast-enhanced sonography were adopted. mRNA and protein level of CD/TK gene were detected by RT-PCR and Western blot, respectively. To evaluate the anti-tumor effect of CMBs\( \alpha_v\beta_3 \), HCC cells with CMBs\( \alpha_v\beta_3 \) were exposed to 5-fluorocytosine / ganciclovir (5-FC/ GCV). Then, cell cycle distribution after treatment were detected by PI staining and flow cytometry. Apoptotic cells death were detected by optical microscope and assessed by MTT assay and TUNEL-staining assay.
Results

CMBs\textsubscript{av\beta3} had a regular shape and good dispersion. Compared to CMBs, CMBs\textsubscript{av\beta3} had more stable concentrations of \(\alpha\beta_3\) ligand and pEGFP-KDRP-CD/TK, and CMBs\textsubscript{av\beta3} was much sticker to HepG2 HCC cells than normal liver L-02 cells. Moreover, after exposed to anti-\(\alpha\beta_3\) monoclonal antibody, the adhesion of CMBs\textsubscript{av\beta3} to HepG2 cells and L-02 cells were significantly reduced. Also, CMBs\textsubscript{av\beta3} demonstrated a substantially higher efficiency in pEGFP-KDRP-CD/TK plasmid transfection in HepG2 cells than CMBs. In addition, CMBs\textsubscript{av\beta3} could significantly facilitate 5-FC/GCV-induced cell cycle arrest in S phase. Moreover, treatment of 5-FC/GCV combined with CMBs\textsubscript{av\beta3} resulted in a marked apoptotic cell death in HepG2 and SK-Hep-1 HCC cells. In vitro, treatment of 5-FC/GCV combined with CMBs\textsubscript{av\beta3} suppressed cell proliferation. In nude mice model, 5-FU + GCV combined with plasmid + CMBs\textsubscript{av\beta3} were able to significantly suppress tumor volumes.

Conclusion

Through biotin-avidin mediation system, CMBs\textsubscript{av\beta3} were successfully generated to specifically target HCC HepG2 cells. More importantly, CMBs\textsubscript{av\beta3} could significantly facilitate 5-FC/GCV-induced cell cycle arrest and apoptotic cell death in HepG2 cells. Our study demonstrated a potential strategy that could be translated clinically to improve liver tumor gene delivery.

Introduction

Hepatocellular carcinoma (HCC), one of the most common malignant tumor with a high incidence and mortality in the world, threatens people’s life during past decades [1]. With the development of molecular biology and genetic engineering, gene therapy has become a potential approach in treating liver cancer. Suicide gene therapy, with its unique mechanisms, has been rapidly developed and attracted considerable attention [2, 3]. Using this approach, a suicide gene that encodes toxic protein under particular conditions can be delivered to target cells and effectively results in cell death, some suicide genes could also inhibit tumor cell growth by inducing apoptosis [4]. Thymidine kinase (TK) and E.coli cytosine deaminase (CD) are two most common suicide genes. Effective transfection and expression of TK/CD in tumor cells could facilitate both the direct killing effect and bystander effect of 5-FU/GCV [5]. In our previous study, we have constructed pEGFP-KDRP-CD/TK plasmid, which contains CD/TK double suicide gene driven by KDR promoter, and reported that the enhanced CD/TK gene transfection mediated by ultrasound microbubbles (MBs) was effective in killing breast cancer cells [6].

Successful gene therapy requires safe and efficient gene vectors and gene delivery methods. Current viral vector in gene therapy have several problems, including immunogenicity, potential tumorigenicity and low carrying capacity [7]. Liposomes as non-viral vectors can easily be swallowed by phagocytic system and cannot maintain a long life cycle [8]; therefore, it is crucial for researchers to develop more efficient and accurate gene vectors. Ultrasound-targeted microbubble destruction (UTMD) has been reported to provide a non-invasive, safe, and repeatable method for gene delivery [9–11]. Mechanical and cavitation effects generated by UTMD can enhance the temporary permeability of cell membrane and thus facilitate exogenous gene to enter into the targeted cells. The development of ultrasound contrast agent opens up a new idea of carrying target-delivery genes or drugs for chemotherapy in liver tumor patients. In previous study, by using ultrasound & high speed shearing method, we have constructed thrombus—targeted microbubbles and testified its physical and chemical properties.
In previous study, we have constructed thrombus-targeted microbubbles to stably target to blood clots (National invention patent, patent number: ZL200910305811.1).

However, the transfection efficiency of these MBs is somewhat limited since some of the MB-carried plasmids do not accumulate in the target tissue. To further improve gene delivery efficiency, researchers have developed alternate approach by using modified microbubbles with a positively charged surface [13, 14]. CMBs can be combined with DNA through electrostatic interaction [15]. Moreover, plasmid DNA which charge-coupled onto the surface of CMBs are protected against endonuclease degradation [16]. To further improve plasmid transfection and gene delivery efficiency, our group has developed an inclusion of 1, 2-dis-tearoyl-3-trimethylammoniumpropane (Fig 1, DTAP; Avanti, Alabaster, AL, USA) imparted with a positive surface charge.

However, some studies report that the efficiency of UTMD-mediated gene delivery with CMBs is still limited [17]. Conjugating receptor ligands or antibodies to CMBs surface might be a promising approach to overcome this limitation. Angiogenesis is fundamental in tumor growth and metastasis [18,19]. Avβ3 integrin, a well-established biomarker of tumor angiogenesis, is constitutively expressed in low level in quiescent endothelial cells but overexpressed in tumor endothelial cells during tumor angiogenesis [20, 21]. Because of its pivotal role in tumor growth and migration, αvβ3 integrin has been selected as potential therapeutic target in cancers [22, 23]. As widely described in previous studies, microbubbles conjugated with designed antibody are able to specifically bind to target cells or tissues [24, 25].

In this study, to improve the tissue-specificity and transfection efficiency of gene therapy in liver cancer, we synthesized a cationic microbubble with an antibody against αvβ3 integrin. Based on our previously demonstrated technique of ultrasound & high speed shearing in thrombus—targeted microbubbles, we constructed a CD/TK gene specific-delivery CMBs<sub>αvβ3</sub> system in HepG2 cells (Fig 1). We showed that these CMBs<sub>αvβ3</sub> could be accumulated around HepG2 cells and with increased DNA-binding capacity. Moreover, we found that, compared with non-targeted CMBs, CMBs<sub>αvβ3</sub> would enhance 5-FC/TK-induced cell cycle arrest in S phase and facilitate apoptotic cell death in HepG2 cells.

**Materials and Methods**

**Materials**

1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dipalmitoyl phosphatidylcholine (DPPC) and biotinylated dipalmitoylphosphatidyl-ethanolamine (DSPE-PEG2000-Biotin)

![Schematic diagram of CMBs<sub>αvβ3</sub> in specifically targeting human liver cancer HepG2 cells. The interaction between biotin and avidin is highly specific. Avβ3 integrin antibodies on the surface of microbubbles can bind to αvβ3 integrin receptors in HepG2 cells, which resulted in selective accumulation and longer resident time of CMBs<sub>αvβ3</sub> in liver cancer tissue.](https://doi.org/10.1371/journal.pone.0158592.g001)
were purchased from Avanti PolarLipids Inc. (Alabaster, AL, USA). The inclusion of 1, 2-distearyl-3-trimethyl-ammonium-propane (DTAP; Avanti, Alabaster, AL, USA) imparted the agents with a positive surface charge [26]. Human liver cancer HepG2 cells, human liver normal L-02 cells, SK-Hep-1 HCC cells, and lung adenocarcinoma A549 cells were purchased from Xiangya cell bank, Central South University (Changsha, China). Biotinylated anti-αvβ3 antibody and rhodamine mouse anti-human immunoglobulin (Ig) G were obtained from Beijing Biosynthesis Biotechnology Co., LTD. Perfluorinated propane (C3F8) was purchased from the Special gas Co., LTD. Factory (Nanjing, China).

Plasmids
As described in our previous study, the restructured plasmid pEGFP-KDRP-CD/TK coding for green fluorescent protein (GFP) contained CD/TK double suicide gene and was driven by KDR promoter [27]. The molecular weight of this plasmid is 2300 kDa with 3486 bp. The plasmid was amplified and then isolated and purified using QIAGEN plasmid giga kit (Qiagen, Valencia, CA, USA) following the manufacturer’s protocol.

Preparation of non-targeting cationic microbubbles (CMBs)
DSPC, DPPC, DTAP and DSPE-PEG-Biotin were mixed in a 5 ml plastic tube to form a suspension at a molar ratio of 46: 36: 8: 2. Following lyophilization, 1 ml of phosphate-buffered saline (PBS) was added to the samples to rehydrate them and then C3F8 gas was slowly injected into the container to replace the air. Samples were then agitated using an ultrasonic mechanical vibrator with high speed shearing method for 90 sec to form a milky white solution.

Preparation of αvβ3 antibody-conjugated cationic microbubbles (CMBsαvβ3)
Avβ3 antibody was conjugated to the distal end of the DSPE-PEG2000-Biotin molecules through biotin-streptavidin coupling chemical method [28]. Briefly, 500 μl CMBs (1x10^9/ml) were mixed with 100 μg biotinylated anti-αvβ3 antibody in an ultrasonic agitating reaction for 30 min. Then, after centrifugation at 50 g for 5 min, the upper layer (CMBsαvβ3) was washed with PBS three times and then collected. The morphology and particle distribution of CMBsαvβ3 was observed by optical microscopy. The particle size and surface potential were measured by a Zetasizer 3000HS (Malvern, Worcestershire, UK). All experiments were performed for five times.

Determination of plasmid and αvβ3 antibody binding onto the CMBsαvβ3 surface by fluorescent microscope and flow cytometry
To confirm conjugation of the αvβ3 antibody and plasmid to the CMBs, CMBsαvβ3 were diluted to a concentration of 7.8x10^7 in 1.5 ml sterile 0.9% saline, 500 μg plasmids and 500 mL of the CMBsαvβ3, and then mixed. The mixture was then incubated at room temperature with occasional shaking for 30 min. After incubation, unbound plasmids were removed by centrifugal washing for 5 min at 400g in 5 mL PBS for twice. The remaining pallet was resuspended in 0.5 mL PBS. To characterize these CMBsαvβ3, the plasmid was labeled with the nucleotide-avid fluorophore YOYO-1 and αvβ3 ligand was labeled with 14.8 ug/ml rhodamine mouse anti-human immunoglobulin (Ig) G. Fluorophore was incubated with the plasmid conjugated MB dispersion at 3 μg per 1 x 10^9 MBs for 25 min at room temperature. And unbound fluorophores was removed by two rounds of centrifugal washing. These microbubbles were then counted and resuspended in PBS. Plasmid and the antibody conjugation to CMBsαvβ3 was
observed under a fluorescence microscope (CKX41; Olympus, Tokyo, Japan). The binding rate was assessed by flow cytometry (Becton-Dickinson, Franklin Lakes, NJ).

Rosette formation assay
HepG2 HCC cells and normal liver cell L-02 cells were cultivated in a 24-well plate with DMEM containing 10% fetal bovine serum in an incubator with 5% CO2 at 37°C. 5x10^4/ml HepG2 cell and L-02 cells were digested with 2.5 g/L trypsin and incubated with CMBs_{αvβ3} or CMBs (1x10^8/ml) at room temperature for 30 min. To block the rosette formation, HepG2 cells were pre-incubated with biotinylated αvβ3 antibody at room temperature for 30 min before the cells were incubated with CMBs_{αvβ3} or CMBs for 30 min. After removing the unbound microbubbles, the resulting mixture (final volume 5 ml) was examined under microscope and the cells that formed rosette were counted.

Gene transfection
100 μl HepG2 or L-02 cell suspension was mixed with 50 μl of CMBs_{αvβ3} containing pEGFP-KDRP-CD/TK plasmid. The ultrasonic therapy device ACUSON S2000 (SEMENS, USA) was preheated for 30 min. Then the ultrasound probe coated with coupling agent was put close to the bottom of the cell culture plates to sonicate the microbubbles (2 MHz, P = 0.75 W/cm2, t = 45s). 48 hours after sonication, EGFP expression was observed by an inverted fluorescence microscope. The transfection efficiency was determined using the formula: (Number of positive cells expressing EGFP/Total number of viewed cells) x100%.

RT-PCR and Immunoblotting
The total RNA of the cells was extracted by Trizol Reagent. Upstream and downstream primers of CD/TK was used for PCR reaction and 4 μl PCR amplified products were detected by electrophoresis on a 1.5% agarose gel. And CD/TK were measured by Western blot using anti-Thymidine kinase antibody and anti-CDA antibody (Millipore, Billerica, MA).

Total cell lysates were harvested, subjected to 12% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes (Roche, Basel, Switzerland). Immunoblotting involved incubation with the primary antibodies followed by the addition of secondary antibodies conjugated to horseradish peroxidase (Cell Signaling) to facilitate detection. Subsequently, enhanced chemiluminescence reagent (Cell Signaling) was added to develop the blots.

Analysis of cell cycle arrest and apoptosis
To determine the effects of CMBs_{αvβ3} containing pEGFP-KDRP-CD/TK plasmid on the cell cycle, propidium iodide (PI) staining after 75% alcohol fixation was used, followed by flow cytometry analysis. Featured apoptotic cell death was detected by optical microscope. 5x10^4/ml HepG2 cells with or without treatment were observed at 24, 48 and 72 hours after treatment. For apoptotic cells, DNA fragmentation was detected by the terminal deoxynucleotidyltransferase mediated dUTP nick end labeling (TUNEL) assay (Roche Applied Science, Pennsburg, Germany). For the TUNEL assay, cells with or without treatment were固定ized with 4% paraformaldehyde in PBS for 20 min, and then washed with PBS for 30 min and incubated with permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) for 2 min on ice. Cells were washed twice and incubated in a humidified atmosphere with TUNEL reaction mixture for 60 min at 37°C in the dark. Then, 50ul POD was added and incubated for 20–30 min at 37°C. After washed by PBS for three times, 50-100ul DAB was added and incubated for 5–10
min. After washed by PBS, hematoxylin stained for 10–30 sec and then was washed away. Finally, cells were analyzed under an optical microscope.

**MTT assay**
After treatment, 50 μl MTT was added into each well in 96-well plates, and then mixed with cells. And then the cells were treated with different concentration of 5-FC (20mg/l, 40mg/l, 60mg/l, ... ) and GCV (0.02 mg/l, 0.1mg/l, 0.25mg/l, ... ) according to the different groups. After incubation with MTT for 30 minutes, cell viability was measured by the optical density (OD) value of each well by an enzyme-linked immunosorbent assay instrument at 490 nm. Each concentrationand treatment time point has three duplicates. The rate of cellular inhibition was determined using the formula: (1-OD value in treatment group/OD value in control group) x100%.

**In vivo treatment**
Tumor xenograft animal model was constructed following protocol [29]. 30 nude mice bearing HepG2 liver cancer were randomly divided into 5 groups. For group 1, normal saline (NS) were administrated by intraperitoneal injection daily. In group 2, 160mg/kg 5-FC and 100mg/kg GCV were administrated by intraperitoneal injection daily. In group 3, 40ug plasmid was injected from posterior venous plexus on day 1 and 2, with 5-FC + GCV daily injection. In group 4, 80ul microbubble was injected from posterior venous plexus and followed by ultrasound wave irradiation (1MHz, 2w/cm², 50% duty cycle, irradiation for 10s with 10s stop, 5 min in total) for 2 days. In group 5, 2 day treatment of 40ug plasmid + 80ul microbubble and ultrasound wave irradiation was coupled with 5-FC + GCV daily. The total treatment duration was 10 days. The tumor growth was observed and tumor volumes were calculated. Then, HepG2 xenografts were removed and weighted. Immunohistochemical staining was used to detect the expression levels of CD31. Apoptotic cells were detected by TUNEL. The detailed procedures were described in reference paper [30].

**Statistical analysis**
All data are expressed as mean ± standard deviation (SD), unless otherwise noted. Differences among groups were analyzed by one-way ANOVA and LSD method for multiple comparisons among groups using the SPSS software package (Version 19.0 for windows, SPSS, Chicago, Illinois, USA) with p < 0.05 considered statistically significant.

**Results**

**Morphology and coupling assessment of microbubble**
The morphology of polydisperse gas-encapsulated CMBs$_{αvβ3}$ was assessed by light microscopy. As shown in Fig 2A, CMBs$_{αvβ3}$ was homogeneously distributed and relatively uniform without adhesion and aggregation. As measured by electrozone sensing with a Coulter counter, the mean diameter of CMBs$_{αvβ3}$ was 1.97 μm, and the concentration was 5.2x10$^5$ bubbles/mL.

To assess the conjugation strength of plasmid and α$_v$β$_3$ integrin antibody with CMBs$_{αvβ3}$, spectrophotometer and flow cytometry assays were adopted. After incubation with CMBs$_{αvβ3}$, plasmid and the antibody conjugation to CMBs$_{αvβ3}$ was observed under fluorescence microscope. The green and red fluorescence signal indicated the binding strength of YOYO-1–labeled plasmid and Rhodamine–labeled α$_v$β$_3$ integrin antibody to CMBs$_{αvβ3}$, respectively. As shown in Fig 2B, bright green fluorescence signals were observed on the surface of CMBs$_{αvβ3}$ and demonstrated that the plasmid was tightly connected to the CMBs$_{αvβ3}$. The red fluorescent
Cationic Microbubbles Carrying Gene and Antibody in HCC HepG2 Cells
In HepG2 cells without pre-incubation, the difference of rosette formation rates in CMBs was statistically significant, *p* < 0.05. In HepG2 cells with CMBs incubation was not statistically significant, *p* > 0.05. The difference of rosette formation rates of CMBs in L-02 cells, HepG2 cells without any pre-incubation, and HepG2 cells with pretreatment with different concentrations of anti-αvβ3 monoclonal antibody, the rosette formation rates declined significantly (*p* < 0.05), and little CMBs and CMBs combined with the antibody and plasmid to CMBs demonstrated a tight and efficient combination of the antibody and plasmid to CMBs (Table 1).

**Table 1. Comparison of the rosette formation rates in each group (n = 6, % mean ± SD of three experiments).**

| Group          | L-02 cells     | HepG2 cells
|----------------|----------------|----------------|
|                | Without pre-incubation | Pre-incubution with αvβ3 antibody |
| CMBs<sub>αvβ3</sub> | 34.67 ± 2.08     | 51.67 ± 5.69<sup>a,b</sup> | 3.67 ± 0.57<sup>d</sup> |
| CMBs           | 8.33 ± 1.52<sup>c</sup> | 13.33 ± 6.33<sup>a,c</sup> | 7.33 ± 1.52<sup>c</sup> |

**Note**

a. In HepG2 cells without pre-incubation, the difference of rosette formation rates in CMBs<sub>αvβ3</sub> group and CMBs group was statistically significant, *p* < 0.05.  
b. In HepG2 cells with CMBs<sub>αvβ3</sub>, the difference of rosette formation rates between group with αvβ3 antibody pre-incubation and group without pre-incubation was statistically significant, *p* < 0.05.  
c. The difference of rosette formation rates of CMBs in L-02 cells, HepG2 cells without any pre-incubation, and HepG2 cells with αvβ3 antibody pre-incubation was not statistically significant, *p* > 0.05.

**Fig 2. Morphology and fluorescence image of CMBs<sub>αvβ3</sub>.** A. Under light microscopy (magnification, x400), microbubbles were uniformly distributed with no visible aggregation. Each photo is representative of three experiments. B. Green fluorescence was observed on the surface of CMBs<sub>αvβ3</sub> using immunofluorescent microscopy. Each photo is representative of three experiments. C. Red fluorescence was observed on the surface of CMBs<sub>αvβ3</sub> using immunofluorescent microscopy. Each photo is representative of three experiments. D. Flow cytometry analysis of the αvβ3 antibody and plasmid combined to CMBs<sub>αvβ3</sub> or CMBs. Each histogram is representative of three experiments. E. Comparison of the αvβ3 antibody and plasmid binding efficiencies in cells treated with CMBs<sub>αvβ3</sub> or cells treated with CMBs (mean ± SD of three experiments; *p* < 0.0001).

doi:10.1371/journal.pone.0158592.g002

signals in Fig 2C suggested a successful conjugation of that αvβ3 integrin antibody with CMBs<sub>αvβ3</sub>.

**Combination of the antibody and plasmid to CMBs<sub>αvβ3</sub>**

Both the plasmid and αvβ3 integrin antibody were conjugated on the surface of cationic microbubbles. The binding efficiency of plasmid and αvβ3 integrin antibody with CMBs<sub>αvβ3</sub> was analyzed by flow cytometry. As shown in Fig 2D and 2E, compared with CMBs, about 97.2% CMBs<sub>αvβ3</sub> were combined with the αvβ3 antibody (Fig 2D, right-up panel) while about 99.4% CMBs<sub>αvβ3</sub> combined with the plasmid (Fig 2D, right-bottom panel). These findings demonstrated a tight and efficient combination of the antibody and plasmid to CMBs<sub>αvβ3</sub>.

**Targeting efficiency of CMBs<sub>αvβ3</sub> in Hep2 and L-02 cells**

To examine the targeting efficiency of to HepG2 cells, we compared the rosette formation rate (the number of CMBs<sub>αvβ3</sub> positive cells or CMBs positive cells in 100 cells) in HepG2 cells and L-02 cells (Table 1). Cells combined with more than four CMBs<sub>αvβ3</sub> or CMBs was considered as CMBs<sub>αvβ3</sub> or CMBs positive cells. As observed under the light microscope (Fig 3), when HepG2 cells and normal hepatocytes L-02 cells were incubated with CMBs<sub>αvβ3</sub>, CMBs<sub>αvβ3</sub> aggregated around HepG2 and L-02 cells and formed a rosette-like structure. However, pre-incubation with αvβ3 antibody could block this rosette formation. The rosette formation rate in HepG2 cells (Fig 3A) and L-02 cells (Fig 3B) were 52% and 35%, respectively, indicating a significantly higher targeting efficiency of CMBs<sub>αvβ3</sub> to HepG2 cells than to L-02 cells (*p* < 0.05). The rosette formation rates of CMBs in HepG2 cells (Fig 3C) and L-02 cells (Fig 3D) were 13.33 ± 6.33% and 8.33 ± 1.52%, respectively, much lower than the rosette formation rates of CMBs<sub>αvβ3</sub> to HepG2 cells than CMBs. In addition, after pretreated with different concentrations of anti-αvβ3 monoclonal antibody, the rosettes formation rates declined significantly (*p* < 0.05), and little CMBs and CMBs<sub>αvβ3</sub> were aggregated around HepG2 cells (Fig 3E and 3F).

**Table 1. Comparison of the rosette formation rates in each group (n = 6, % mean ± SD of three experiments).**

| Group          | L-02 cells     | HepG2 cells
|----------------|----------------|----------------|
|                | Without pre-incubation | Pre-incubulation with αvβ3 antibody |
| CMBs<sub>αvβ3</sub> | 34.67 ± 2.08     | 51.67 ± 5.69<sup>a,b</sup> | 3.67 ± 0.57<sup>d</sup> |
| CMBs           | 8.33 ± 1.52<sup>c</sup> | 13.33 ± 6.33<sup>a,c</sup> | 7.33 ± 1.52<sup>c</sup> |

**Note**

a. In HepG2 cells without pre-incubation, the difference of rosette formation rates in CMBs<sub>αvβ3</sub> group and CMBs group was statistically significant, *p* < 0.05.  
b. In HepG2 cells with CMBs<sub>αvβ3</sub>, the difference of rosette formation rates between group with αvβ3 antibody pre-incubation and group without pre-incubation was statistically significant, *p* < 0.05.  
c. The difference of rosette formation rates of CMBs in L-02 cells, HepG2 cells without any pre-incubation, and HepG2 cells with αvβ3 antibody pre-incubation was not statistically significant, *p* > 0.05.

doi:10.1371/journal.pone.0158592.l001
Transfection efficiency of CMBs \(\alpha_v\beta_3\) in HepG2 and L-02 cells

As demonstrated in Fig 4, at 24 h after CMBs \(\alpha_v\beta_3\) transfection, EGFP expression levels in HepG2 cells and L-02 cells were evaluated by fluorescence microscope (Fig 4A and 4B). The number of cells expressed EGFP was counted (200×). The transfection efficiency was determined using the formula: 

\[
\text{Transfection efficiency} = \left( \frac{\text{Number of positive cells expressing EGFP}}{\text{Total number of viewed cells}} \right) \times 100\%.
\]

The percentage of positive cells were 81.67 ± 3.51% in HepG2 cells and 37.67 ± 1.53% in L-02 cells (\(P < 0.05\)), suggesting a significant higher transfection efficiency of CMBs\(\alpha_v\beta_3\) in HepG2 cells than in L-02 cells. Besides HepG2 cells, CMBs\(\alpha_v\beta_3\) transfection was detected in lung adenocarcinoma A549 cells and SK-Herp-1 HCC cells (Fig 4E and 4F).
Fig 4. Transfection efficiency of CMBs_{\alpha v\beta 3} and Expression of CD/TK in HepG2 and L-02 cells. A and B. EGFP expression levels in HepG2 cells (A) and L-02 cells (B) were detected using fluorescence. 10 visions were chosen at random and each experiment was repeated for three times (mean ± SD of three experiments). C. mRNA expression of the Cationic Microbubbles Carrying Gene and Antibody in HCC HepG2 Cells.
Expression of CD/TK in HepG2 and L-02 cells

After pEGFP-KDRP-CD/TK was transfected into HepG2 and L-02 cells, we found that there was a marked mRNA expression of the target gene CD/TK in HepG2 and L-02 cells by RT-PCR detection (Fig 4C). Bands at 381bp (CD) and 355bp (TK) were observed in both HepG2 and L-02 cells with CMBs\(\alpha_v\beta_3\) CD/TK plasmid transfection. CD/TK bands were not observed in HepG2 and L-02 cells with only CMBs treatment. Moreover, Fig 4C showed that compared to L-02 cells, CD/TK mRNA expression was significantly higher in HepG2 cells with CMBs\(\alpha_v\beta_3\) CD/TK plasmid transfection. The highest TK expression level was observed in HepG2 cells with CMBs\(\alpha_v\beta_3\) CD/TK plasmid transfection, which was consistent with the RT-PCR results. Moreover, CD/TK protein expression level was higher in SK-Herp-1 HCC cells than A549 cells (Fig 4G).

CMBs\(\alpha_v\beta_3\) facilitates 5-FC/GCV-induced cell cycle arrest at S phase in HepG2 cells

To investigate the effect of CMBs\(\alpha_v\beta_3\) in 5-FC/GCV-treated HepG2 cells, PI staining and flow cytometry were firstly adopted to analyze the cell cycle distribution. As shown in Fig 5, compared with untreated HepG2 cells, 5-FC (64ug/ml) /GCV (320ug/ml) could arrest 35.3%, 31.05% and 55.68% HepG2 cells at S phase of the cell cycle at 24, 48 and 72 hours after treatment, respectively. When combined with ultrasound and CMBs\(\alpha_v\beta_3\), 41.94%, 51.81% and 70.40% HepG2 cells were arrested in S phase of the cell cycle at 24, 48 and 72 hours after treatment, respectively, which were significantly higher than 5-FC / GCV treatment alone. These findings implied that CMBs\(\alpha_v\beta_3\) could facilitate 5-FC/GCV-induced cell cycle arrest at S phase in HepG2 cells.

CMBs\(\alpha_v\beta_3\) induces apoptosis in HepG2 cells

As shown in Fig 6, no obvious morphological change was occurred in untreated HepG2 cells (control) within 72 hours, while some of HepG2 cells underwent apoptotic cell death with characteristic morphological changes at 48 and 72 hours after 5-FC (64ug/ml) /GCV (320ug/ml) treatment. Moreover, when 5-FC/GCV combined with ultrasound and CMBs\(\alpha_v\beta_3\), more apoptotic HepG2 cells were observed at 24, 48 or 72 hours after treatment, which were significantly higher than 5-FC / GCV treatment alone. MTT assay demonstrated that the inhibition rate of HepG2 cells treated with 5-FC / GCV and CMBs\(\alpha_v\beta_3\) was significantly greater than that of cells treated with only 5-FC+GCV at different concentrations (Fig 6C). Also, in SK-Herp-1 HCC cells, 5-FC / GCV and CMBs\(\alpha_v\beta_3\) was more effective than 5-FC+GCV alone (S1 Fig).

To further confirm 5-FC / GCV + CMBs\(\alpha_v\beta_3\) induces apoptosis in HepG2 cells, TUNEL assay was adopted. Fig 7A illustrated HepG2 cells with TUNEL staining after UTMD-mediated CD/TK plasmid delivery. Nuclei were stained blue with DAPI. In 5-FC/GCV-treated HEPG2 cells (control), the TUNEL-positive (apoptotic cells) were minimal at 24 and 48 hours. However, in HepG2 cells treated with 5-FC/GCV and ultrasound plus CMBs\(\alpha_v\beta_3\), the number of
Fig 5. Effect of CMBs\textsubscript{\(\alpha_v\beta_3\)} in 5-FC / GCV—induced cell cycle arrest in HepG2 cells. A. Cell cycle analysis of untreated HepG2 cells and HepG2 cells treated with 5-FC / GCV, 5-FC / GCV + ultrasound, or 5-FC / GCV + ultrasound + CMBs\textsubscript{\(\alpha_v\beta_3\)} for 24, 48 and 72 hours, as analyzed by flow cytometry and PI staining. Each histogram is representative of three experiments. B. The effects of 5-FC / GCV + ultrasound + CMBs\textsubscript{\(\alpha_v\beta_3\)} treatment on the cell cycle distribution of HepG2 cells were analyzed using Multicycle software program (Phoenix Flow System) (mean ± SD of three experiments; *p < 0.01).
Cationic Microbubbles Carrying Gene and Antibody in HCC HepG2 Cells

A.

| Time   | Control | Ultrasound | Ultrasound + CMBs_{pdG} | 5-FC+GCV | 5-FC+GCV+ultrasound | 5-FC+GCV+ultrasound + CMBs_{pdG} |
|--------|---------|------------|--------------------------|----------|---------------------|----------------------------------|
| 24 hr  | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) | ![Image](image4.png) | ![Image](image5.png) | ![Image](image6.png) |
| 48 hr  | ![Image](image7.png) | ![Image](image8.png) | ![Image](image9.png) | ![Image](image10.png) | ![Image](image11.png) | ![Image](image12.png) |
| 72 hr  | ![Image](image13.png) | ![Image](image14.png) | ![Image](image15.png) | ![Image](image16.png) | ![Image](image17.png) | ![Image](image18.png) |

B.

![Graph](image19.png)

C.

![Graph](image20.png)

![Graph](image21.png)

![Graph](image22.png)
TUNEL-positive apoptotic cells increased significantly at 24 and 48 hours after treatment ($p < 0.05$). Quantitative analysis demonstrated that the number of apoptotic cells (TUNEL-positive cells) was highest in HepG2 cells treated with 5-FC/GCV and ultrasound plus CMBs $\alpha v \beta 3$ ($p < 0.05$).

CMBs $\alpha v \beta 3$ suppresses tumor growth in HepG2 xenograft mice

To investigate the anti-tumor effect of CMBs $\alpha v \beta 3$ in vivo, we applied HepG2 xenograft mice model. As shown in Fig 8A, compared with control group (NS), 5-FU + GCV or 5-FU + GCV + plasmid could not significantly suppress tumor volume at seven days after treatment (treatment duration was 10 days). However, when 5-FU + GCV combined with plasmid + CMBs $\alpha v \beta 3$ was able to effectively suppress tumor growth, compared with 5-FU + GCV or 5-FU + GCV + plasmid treatment ($p < 0.05$). Moreover, compared with control group, both CMBs $\alpha v \beta 3$ treatment alone and 5-FU + GCV combined with plasmid + CMBs $\alpha v \beta 3$ were able to significantly suppress tumor volumes ($p < 0.05$).

To determine whether CMBs $\alpha v \beta 3$ treatment facilitate 5-FU + GCV–induced apoptotic cell death in liver cancer cells in vivo, tumor sections from HepG2-bearing nude mice were stained with TUNEL to identify the apoptotic cell population. As shown in Fig 8B and 8C, treatment with 5-FU + GCV or 5-FU + GCV + plasmid did not appreciably induce apoptosis. Treatment with CMBs $\alpha v \beta 3$ alone and 5-FU + GCV combined with plasmid + CMBs $\alpha v \beta 3$ stimulated a substantially increased number of TUNEL-positive cells in tumor sections, as indicated by vacuolated and brown-nuclear cells (arrow heads). 5-FU + GCV with plasmid + CMBs $\alpha v \beta 3$ induced more TUNEL-positive cells than 5-FU + GCV alone ($p < 0.05$, Fisher’s exact test).

Discussion

CMBs $\alpha v \beta 3$ were successfully synthesized and conjugated with a $\alpha, \beta, \gamma$ antibody using bio-conjugation. CMBs $\alpha v \beta 3$ had a regular shape and good dispersion, and showed significantly greater adhesion to HepG2 cells than CMBs, specifically when targeting HepG2 cells. Importantly, our data also demonstrated that delivery of the pEGFP-KDRP-CD/TK plasmid by CMBs $\alpha v \beta 3$ resulted in a substantially greater gene transfection efficiency. Therefore, this CMBs $\alpha v \beta 3$ is an important advance that could be translated clinically to improve gene delivery in liver cancer therapy.

We previously established a CD/TK suicide gene system in which CD/TK gene expression was modified by tumor tissue-specific promoter KDRP, as pEGFP-KDRP-CD/TK. The transfection of this CD/TK suicide gene system was mediated by ultrasound microbubbles and led to specific killing-effect on cancer cells[6]. Though UTMD has been reported to provide a non-invasive, safe, and repeatable method for gene delivery[10, 11, 31] and contrast agents intravenously injected are used as carriers for genes or drugs, the therapeutic effects were somewhat limited because the plasmids did not accumulate in the target tissue. Ways to improvement include enhancing the genes carrying by the microbubble contrast agents and increasing the targeting abilities of the microbubble through changing its surface feature.

Positively charged microbubbles possess increased carrying capacity for negatively charged plasmid DNA[14, 15]. However, some studies still report the limited efficiency of UTMD-mediated gene delivery even with CMBs[17]. To increase the therapeutic potential of CMBs,
Fig 7. A. HepG2 cells were treated with 5-FC / GCV, 5-FC / GCV + ultrasound, or 5-FC / GCV + ultrasound + CMBs for 24, 48 and 72 hours. TUNEL-positive apoptotic cells were observed in HepG2 cells (Magnitudes×40). B. Numbers of TUNEL-positive cells in each treatment group were counted for five different visual fields (mean ± SD of three experiments; *p < 0.05).

doi:10.1371/journal.pone.0158592.g007
it's a hopeful approach by conjugating receptor ligands or antibodies to their surface. Angiogenesis, the growth of new blood vessels from existing vessels, is a fundamental component of tumor growth and metastasis [18, 19]. αvβ3 integrin is the best-characterized molecular markers of tumor angiogenesis and plays a pivotal role in tumor growth and migration, thus it has been selected as targets for therapeutic strategies successfully in cancer [20, 21]. Therefore, microbubbles conjugated with antibodies against αvβ3 integrin would share feasible targeting ability to tumor tissues.

The value of our CMBsαvβ3 is its capacity for targeted tissue binding and efficient gene delivery. Here we synthesized a CD/TK delivery cationic microbubble as CD-TK/ CMBsαvβ3 conjugated with αvβ3 antibody using poly(ethylene glycol)-biotin-streptavidin. In this study, firstly, the fluorescence of GFP or anti-αvβ3 approved the CD/TK gene and αvβ3 have been successfully carried by the microbubble, with further confirmed through flow cytometry. Then we demonstrated that the CMBsαvβ3 exhibited significantly greater human liver HepG2 cell binding compared with the non-targeted CMBs. And the adhesion of CMBsαvβ3 to human liver HepG2 cell and L-02 cells were reduced significantly after pre-administration of anti-αvβ3 monoclonal antibody, which indicates the adhesion is liver tumor cell specific and αvβ3 mediated. Importantly, our data also demonstrated that CMBsαvβ3 delivery of the CD/TK plasmid resulted in substantially great gene transfection efficiency, validated by fluorescence, PCR and western blot. In this study, we also found that CMBsαvβ3 could facilitate 5-FC/GCV-induced cell cycle arrest at G phase in HepG2 cells after PI staining and flow cytometry. And MTT assay demonstrated that the inhibition rate of HepG2 cells treated with 5-FC / GCV and CMBsαvβ3 was significantly greater than that of cells treated with only 5-FC + GCV at different concentrations. Quantitative analysis demonstrated that the number of apoptotic cells (TUNEL-positive cells) was highest in HepG2 cells treated with 5-FC/GCV and ultrasound plus CMBsαvβ3 (p<0.05). Therefore this CMBsαvβ3-based CD/TK suicide gene delivery system is definitely effective and an important advance that could be translated clinically to improve suicide gene therapy for liver cancer and other malignant tumors, though in vivo experimental research are warranted before its clinical translation.

Conclusions

CMBsαvβ3 specifically targeting human liver cancer HepG2 cells were successfully prepared through biotin-avidin mediation. Numerous problems of targeting contrast agents remain, including the stability in the blood or the induced immune response, which require further investigation. However, our study demonstrated that the novel CMBsαvβ3 were able to specially target the CD/TK gene to the HepG2 cells and could be potentially applied in targeted gene delivery and therapy of cancer. This technique may be of significant utility in the field of molecular imaging, both in the setting of research and clinical practice.

Supporting Information

S1 Fig. The effect of CMBsαvβ3 in 5-FC / GCV—induced anti-proliferation in SK-Hep-1 HCC cells was measured by MTT assay. 5-FC / GCV with ultrasound plus CMBs was served
as control (mean ± SD of three experiments; *p < 0.05).

(S2 Fig. The effect of CMBsαvβ3 in 5-FC / GCV—induced anti-proliferation in A549 cells was measured by MTT assay. 5-FC / GCV with ultrasound plus CMBs was served as control (mean ± SD of three experiments; *p < 0.05).

Acknowledgments

Our work was funded by a grant from National Natural Science Foundation of China (81271680) and PingZhou received the funding. And PingZhou was the person making decisions to publish.

Author Contributions

Conceived and designed the experiments: PZ JL. Performed the experiments: JL LL. Analyzed the data: YZ. Contributed reagents/materials/analysis tools: ST. Wrote the paper: JL PZ. Designed the software used in analysis: YS LT.

References

1. Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW, Ji MF, et al. Incidence and mortality of liver cancer in China, 2010. Chin J Cancer, 2014; 33(8): 388–94. doi: 10.5732/cjc.014.10088 PMID: 25104174
2. Kojima Y, Honda K, Hamada H, Kobayashi N. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J Surg Res, 2009; 157(1): e63–70. doi: 10.1016/j.jss.2008.12.016 PMID: 19345377
3. Vassaux G, Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. ExpertOpinBiolTher, 2004; 4(4): 519–30.
4. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res, 2001; 7(11): 3314–24. PMID: 11705842
5. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions, Hum Gene Ther. 1998; 9: 2385–2391. PMID: 9629537
6. Li XH, Zhou P, Wang LH, Tian SM, Qian Y, Chen LR, et al. The targeted gene (KDRP-CD/TK) therapy of breast cancer mediated by Sonovue and ultrasound irradiation in vitro. Ultrasonics, 2012; 52(1): 186–96. doi: 10.1016/j.ultras.2011.08.002 PMID: 21906771
7. Barry MA, Holtherr SE, Chen CY, Senac JS, Hillestad ML, Shashkova EV. Systemic delivery of therapeutic viruses. CurrOpinMolTher, 2009; 11(4): 411–20.
8. Gao Y, Liu XL, Li XR., Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine, 2011; 6: 1017–25. doi: 10.2147/IJNN.S17040 PMID: 21720513
9. Fujii H, Li SH, Wu J, Miyagi Y, Yao TM, Rakowski H, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J, 2011; 32(16): 2075–84. doi: 10.1093/eurheartj/ehq475 PMID: 21196445
10. Cui K, Yan T, Luo Q, Zheng Y, Liu X, Huang X, et al., Ultrasound microbubble-mediated delivery of integrin-linked kinase gene improves endothelial progenitor cells dysfunction in pre-eclampsia. DNA Cell Biol, 2014; 33(5): 301–10. doi: 10.1089/dna.2013.2229 PMID: 24564279
11. Suzuki J, Ogawa M, Takayama K, Taniyama Y, Morishita R, Hirata Y, et al., Ultrasound-microbubble-mediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice. J Am CollCardiol, 2010; 55(9): 904–13.
12. Gao F, Ding Y, Sheng X, Wang W, Liang Q, Luo Z, et al. Preparation and preliminary evaluation of KGDS-targeted ultrasound contrast agent. Zhong Nan Da XueXueBao Yi Xue Ban, 2009; 34(12): 1255–60.
13. Wang DS, Panje C, Pysz MA, Paulmurugan R, Rosenberg J, Gambhir SS, et al. Cationic versus neutral microbubbles for ultrasound-mediated gene delivery in cancer. Radiology, 2012; 264(3): 721–32. doi: 10.1148/radiol.12112368 PMID: 22723497
14. Panje CM, Wang DS, Pysz MA, Paulmurugan R, Ren Y, Tranquart F, et al. Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. Theranostics, 2012; 2(11): 1078–91. doi: 10.7150/thno.4240 PMID: 23227124
15. Phillips LC, Klibanov AL, Bowles DK, Ragosta M, Hossack JA, Wamhoff BR. Focused in vivo delivery of plasmid DNA to the porcine vascular wall via intravascular ultrasound destruction of microbubbles. J Vasc Res, 2010; 47(3): 270–4. doi: 10.1159/000258805 PMID: 19923850
16. Panje CM, Wang DS, Pysz MA, Paulmurugan R, Ren Y, Tranquart F, et al., Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. Theranostics, 2012; 2(11): 1078–91. doi: 10.7150/thno.4240 PMID: 23227124
17. Sun L, Huang CW, Wu J, Chen KJ, Li SH, Weisel RD, et al. The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium. Biomaterials, 2013; 34(8): 2107–16. doi: 10.1016/j.biomaterials.2012.11.041 PMID: 23453320
18. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature, 2000; 407(6801): 249–57. PMID: 11001068
19. Pralhad T, Madhusudan S, Rajendrakumar K. Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol, 2003; 55(8): 1045–53. PMID: 12956893
20. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994; 264(5158): 569–71. PMID: 7512751
21. Kluz E, van der Schaft DW, Hautvast PA, Mulder WJ, Mayo KH, Griffioen AW, et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett, 2010; 10(1): 52–8. doi: 10.1021/nl902659g PMID: 19968235
22. Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P, Rosenberg J, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology, 2008; 248(3): 936–44. doi: 10.1148/radiol.2483072231 PMID: 18710985
23. Sheldonke HM, Patterson LH. Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets, 2009; 9(4): 519–44. PMID: 19519320
24. Chang S, Guo J, Sun J, Zhu S, Yan Y, Zhu Y, et al., Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells. Ultrasochem, 2013; 20(1): 171–9.
25. Villanueva FS, Jankowski RJ, Klibanov S, Pina ML, Alber SM, Watkins SC, et al., Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation, 1998; 98(1): 1–5. PMID: 9660501
26. Christiansen JP, French BA, Klibanov AL, Kaul S, Lindner JR., Targeted tissue transfection with ultrasound destruction of plasmid-bearing cationic microbubbles. Ultrasound Med Biol, 2003; 29(12): 1759–67. PMID: 14698343
27. Li QM, Kan FJ, Min CY. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells, World J. Gastroenterol. 2002; 8: 994–998. PMID: 12439912
28. Lindner JR, Song J, Xu F, Klibanov AL, Singbartl K, Ley K et al. Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. Circulation, 2000; 102(22): 2745–50. PMID: 11094042
29. Vongchan P, Kothan S, Wutti-Im Y, Linhardt RJ. Inhibition of human tumor xenograft growth in nude mice by a novel monoclonal anti-HSPG isolated from human liver. Anticancer Research, 2011; 31 (12): 4067–4074. PMID: 22199263
30. Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D et al., ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. International Journal of Cancer, 2008; 123(10): 2418–2429. doi: 10.1002/jjc.23752 PMID: 18712728
31. Song S, Shen Z, Chen L, Brayman AA, Miao CH. Explorations of high-intensity therapeutic ultrasound and microbubble-mediated gene delivery in mouse liver. Gene Ther, 2011; 18(10): 1006–14. doi: 10.1038/gt.2011.34 PMID: 21451579